Skip to main content
Clinical Trials/NCT06010511
NCT06010511RecruitingNot Applicable

White Matter Hyperintensity Shape and Glymphatics

Leiden University Medical Center1 site in 1 country50 target enrollmentStarted: January 18, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
50
Locations
1
Primary Endpoint
WMH shape

Study Overview

Brief Summary

In a society with increased life expectancy, the economic, social and personal burden of dementia increases. Dementia is often caused by a combination of neurovascular and neurodegenerative diseases. Impaired brain clearance is suggested to be closely related to dementia development, as waste products (e.g. amyloid beta) accumulate in the brain, leading to neurodegeneration. Cerebral small vessel disease (SVD) is the most common neurovascular disease that even contributes to about 45% of dementia pathophysiology in patients with a diagnosis of Alzheimer's dementia. White matter hyperintensities of presumed vascular origin (WMH) are the key brain MRI manifestation of cerebral SVD. There is evidence that the currently known and MRI-visible WMH are landmarks of an already progressed stage of the underlying pathology. The pathophysiology of WMH has been attributed to multiple underlying mechanisms, such as hypoperfusion, defective cerebrovascular reactivity and blood-brain barrier dysfunction. Furthermore, different anatomical locations and different types of WMH are related to different underlying pathological changes. Using ultra-high field 7T MR imaging techniques WMH lesions can be detected with a higher sensitivity and resolution than on 3T MRI. The hypothesis is that different pathological mechanisms of cerebral SVD lead to variations in WMH shape. Moreover, the brain clearance ('glymphatic') system of the brain appears to be tightly connected to dementia pathology. Thus, novel markers of glymphatic activity could aid to describe and understand the pathology.

Detailed Description

Aim:

The overall aim is to study how different pathological mechanisms in cerebral SVD influence WMH shape.

Primary objective:

To study the association of a more complex WMH shape with abnormalities in small vessel morphology.

Secondary objectives:

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Admitted to the memory or the geriatric clinic of the LUMC, the Alrijne Hospital Leiden or the Haga Hospital the Hague
  • From 65 years of age
  • Eligible for MRI
  • Native-level Dutch speaker

Exclusion Criteria

  • Claustrophobia
  • Contraindications for MRI such as metal implants and pacemaker
  • Use of benzodiazepines
  • Initiated treatment with antidepressants less than 6 weeks prior to inclusion
  • Not being able to provide written informed consent (assessed by the treating physician)
  • Individuals that have been declared mentally incapacitated
  • Other severe neurological disease besides dementia related
  • Cognitive impairment due to known other neurological disease
  • Previous brain surgery

Outcomes

Primary Outcomes

WMH shape

Time Frame: at study visit during inclusion up to 3 years

The investigators will use an in-house developed analysis pipeline to calculate WMH shape on 3T and 7T brain MRI scans. Associations between WMH shape and other SVD markers and cognition will be investigated with linear and logistic regression (at least corrected for age and sex).

Secondary Outcomes

  • Brain clearance(at study visit during inclusion up to 3 years)
  • Perivascular space volume(at study visit during inclusion up to 3 years)
  • WMH subtypes(at study visit during inclusion up to 3 years)

Investigators

Sponsor
Leiden University Medical Center
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jeroen de Bresser

Principal Investigator; MD; PhD

Leiden University Medical Center

Study Sites (1)

Loading locations...

Similar Trials

WHIte MAtter Hyperintensity Shape and... | Clinical Trial